Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 12, 2025 07:00 ET | Source: Climb Bio, Inc.

Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Clinical Trials of Budoprutug in Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) Underway; Trial of Budoprutug in Primary Membranous Nephropathy (pMN) Expected to Initiate in the...
June 18, 2025 07:00 ET | Source: Climb Bio, Inc.

Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer

Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll,...
May 19, 2025 16:34 ET | Source: Climb Bio, Inc.

Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WELLESLEY HILLS, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases,...
May 14, 2025 07:00 ET | Source: Climb Bio, Inc.

Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus (SLE) on Track to Initiate in 2025 CLYM116 Progressing Towards...
April 01, 2025 07:00 ET | Source: Climb Bio, Inc.

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its...
March 27, 2025 07:00 ET | Source: Climb Bio, Inc.

Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference

WELLESLEY, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its executive team will participate at the 24th Annual Needham Healthcare...
March 25, 2025 16:05 ET | Source: Climb Bio, Inc.

Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates

Received Clearance from the U.S. Food and Drug Administration (FDA) for Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus...
February 25, 2025 07:00 ET | Source: Climb Bio, Inc.

Climb Bio to Present at Upcoming Investor Conferences

WELLESLEY, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its executive team will participate in the upcoming investor conferences detailed...
February 24, 2025 07:00 ET | Source: Climb Bio, Inc.

Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer

WELLESLEY HILLS, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) announced today the appointment of Perrin Wilson, Ph.D. as Chief Business Officer. Dr. Wilson is an...
February 04, 2025 07:00 ET | Source: Climb Bio, Inc.

Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

WELLESLEY, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its executive team will participate at the Oppenheimer 35th Annual Healthcare Life...